TY - JOUR T1 - The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden JF - medRxiv DO - 10.1101/2021.09.02.21263046 SP - 2021.09.02.21263046 AU - Catherine Isitt AU - Daniel Sjöholm AU - Maria-Pia Hergens AU - Fredrik Granath AU - Pontus Nauclér Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/07/2021.09.02.21263046.abstract N2 - Vaccination against SARS-CoV-2 started in Region Stockholm, Sweden in December 2020 with those in long-term care facilities or receiving home care vaccinated first followed by those aged over 80 years. In this population-based, retrospective cohort study, we performed a Poisson regression to model the expected incidence of infections and deaths which we compared to the observed incidence and compared this to an unvaccinated control group of those aged 18-79 years. The aim of this study was to measure the early impact of the vaccination programme in Region Stockholm.Infections and deaths reduced substantially amongst the first two groups targeted for SARS-CoV-2 vaccination with an estimated total 3112 infections prevented, and 854 deaths prevented in these two groups from 4 weeks after the introduction of vaccination through to 2nd May 2021.Competing Interest StatementCI has previously received research funding from Pfizer.Funding StatementThe work was supported by grants from Region Stockholm, Swedish Research Council and Emil and Vera Cornell Stiftelse.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical consent was gained from the Swedish Ethical Review Authority.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData was extracted from the VAL database in Region Stockholm. ER -